A 26-WEEK, RANDOMIZED, PARALLEL, TREAT-TO-TARGET TRIAL COMPARING INSULIN DETEMIR WITH NPH INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSELOWERING DRUGS IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES

HERMANSEN, K., DAVIES, M., & DEREZINSKI, T.. (2006). A 26-WEEK, RANDOMIZED, PARALLEL, TREAT-TO-TARGET TRIAL COMPARING INSULIN DETEMIR WITH NPH INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSELOWERING DRUGS IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES. DIABETES CARE, 29(6), 1269-1274. SID. https://sid.ir/paper/641507/en

HERMANSEN K., DAVIES M., DEREZINSKI T.. A 26-WEEK, RANDOMIZED, PARALLEL, TREAT-TO-TARGET TRIAL COMPARING INSULIN DETEMIR WITH NPH INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSELOWERING DRUGS IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES. DIABETES CARE[Internet]. 2006;29(6):1269-1274. Available from: https://sid.ir/paper/641507/en

K. HERMANSEN, M. DAVIES, and T. DEREZINSKI, “A 26-WEEK, RANDOMIZED, PARALLEL, TREAT-TO-TARGET TRIAL COMPARING INSULIN DETEMIR WITH NPH INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSELOWERING DRUGS IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES,” DIABETES CARE, vol. 29, no. 6, pp. 1269–1274, 2006, [Online]. Available: https://sid.ir/paper/641507/en